What is the recommended dosage for Inj. Targocid (teicoplanin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage for Inj. Targocid (Teicoplanin)

For patients with normal renal function, the recommended dosage of Inj. Targocid (teicoplanin) is 30-60 mg/kg/day administered at 6-12 hour intervals, with a loading dose of 25-30 mg/kg for seriously ill patients. 1

Standard Dosing Regimen

  • Initial loading dose: 6-12 mg/kg/dose IV q12h for three doses 1, 2
  • Maintenance dose: 6-12 mg/kg/dose IV once daily 1, 2
  • For seriously ill patients, a higher loading dose of 25-30 mg/kg is recommended 1, 2

Dosing Based on Infection Type

Skin and Soft-Tissue Infections (SSTI)

  • For inpatient complicated SSTI: 6-12 mg/kg/dose IV q12h for three doses, then once daily 1
  • Duration: 7-14 days 1, 2

Bacteremia

  • Uncomplicated bacteremia: 6-12 mg/kg/dose IV q12h for three doses, then once daily 1
  • Complicated bacteremia: 6-12 mg/kg/dose IV q12h for three to six doses, then 6-12 mg/kg/dose once daily 1
  • Duration: 2 weeks for uncomplicated; 4-6 weeks for complicated bacteremia 1, 2

Endocarditis

  • For serious infections such as endocarditis: 12 mg/kg twice daily loading dose is recommended 2
  • Duration: 4-6 weeks for native valve endocarditis; 6 weeks for prosthetic valve endocarditis 2

Pneumonia

  • 6-12 mg/kg/dose IV q12h for three doses, then 6-12 mg/kg/dose once daily 1
  • Duration: 7-21 days 1, 2

Pediatric Dosing

  • Loading dose: 10 mg/kg IV q12h for three doses 1, 2
  • Maintenance dose: 6-10 mg/kg once daily 1, 2

Monitoring Recommendations

  • Routine monitoring of serum levels is not generally required for standard infections 2
  • Monitoring is recommended for patients with S. aureus endocarditis, septic arthritis, major burns, intravenous drug users, or rapidly changing renal function 2
  • Target trough concentration for severe infections such as endocarditis or septic arthritis: ≥20 mg/L 2, 3
  • For most infections, trough levels of 10-15 μg/ml are considered optimal 4

Important Considerations

  • A higher initial dose (800 mg followed by 400 mg for the next two days) has been shown to achieve therapeutic trough levels more reliably than standard dosing (400 mg followed by 200 mg) 4
  • Increased doses of 600 mg daily (after loading) have been associated with improved serum levels without increased toxicity compared to 400 mg daily 5
  • Teicoplanin has a long half-life (terminal half-life of 87 hours), allowing for once-daily administration after initial loading 6
  • Teicoplanin has less potential than vancomycin to cause nephrotoxicity, especially when administered with an aminoglycoside 7
  • Transition from parenteral to oral agents should be done cautiously and is not recommended for patients with complicated bacteremia 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment Duration and Dosing Considerations for Teicoplanin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A critical review of the dosage of teicoplanin in Europe and the USA.

International journal of antimicrobial agents, 1994

Research

Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2006

Research

Clinical pharmacokinetics of teicoplanin.

Clinical pharmacokinetics, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.